文献速递肿瘤 PET/CT

代谢肿瘤体积对晚期霍奇金淋巴瘤疗效反应的预测价值

Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma.
PubMed 文献 · J Nucl Med · 2018-06-07

在德国霍奇金研究组HD18试验中,310例晚期霍奇金淋巴瘤患者于分期时接受18F-FDG PET/CT检查,由中心审查面板用四种阈值法计算代谢肿瘤体积(MTV)。所有MTV算法对PET-2后早期反应的预测能力中等且相近(AUC=0.62-0.63,P=0.01-0.06),但对无进展生存(PFS)和总生存(OS)均无预后价值。

要点

  • 四种MTV阈值法预测PET-2后早期反应的能力中等且相近,AUC=0.62-0.63。
  • ROC曲线未指向任何唯一截断值,而是提示存在较宽的可行截断值范围。
  • 各MTV测量对PFS(HR 1.2-1.5,P=0.15-0.52)和OS(HR 1.0-1.5,P=0.95-0.27)均无预后价值。

核心结论

  • 基线MTV经不同方法测定,是eBEACOPP两周期后早期反应的预测因素。
  • 在高效PET-2适应性治疗策略之后,未观察到MTV作为预后因素的价值。

研究设计与样本

  • 在德国霍奇金研究组HD18试验内,310例晚期霍奇金淋巴瘤患者于分期时接受18F-FDG PET/CT检查,扫描图像可供中心审查面板进行定量分析。
  • 采用四种不同阈值法计算MTV,并用ROC分析评估其对两周期eBEACOPP后PET(PET-2)所定早期反应的预测能力,用逻辑回归评估其对PFS和OS的预后价值。

主要发现

  • 所有不同MTV算法对PET-2反应的预测能力均为中等且相近(AUC=0.62-0.63,P=0.01-0.06)。
  • 没有任何一种测量方法的ROC曲线指向任何唯一截断值,而是提示存在较宽的可行截断值范围。
  • 没有任何MTV测量对PFS有预后价值(HR 1.2-1.5,P=0.15-0.52)。
  • 没有任何MTV测量对OS有预后价值(HR 1.0-1.5,P=0.95-0.27)。

关键数值与推荐

  • 四种MTV阈值法预测PET-2反应的AUC=0.62-0.63,P=0.01-0.06。
  • MTV对PFS的HR=1.2-1.5,P=0.15-0.52。
  • MTV对OS的HR=1.0-1.5,P=0.95-0.27。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: (18F)fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) for staging Hodgkin lymphoma may allow for accurate and reliable assessment of the metabolic tumour volume (MTV) as baseline risk factor. Our aim was to analyse the prognostic impact of MTV measurements, obtained by different means in advanced-stage Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD18 trial. Methods: Within the German Hodgkin Study Group trial HD18, 310 patients underwent 18F-FDG PET/CT scanning for staging which was available to the central review panel for quantitative analysis. We calculated the MTV by four different thresholding methods and performed receiver operating characteristic (ROC) analysis to evaluate the potential for prediction of early response determined by PET after two cycles (PET-2) dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). Logistic regression was used to evaluate its prognostic value concerning progression-free survival (PFS) and overall survival (OS). Results: All different MTV calculations used predicted PET-2 response to a moderate and comparable degree (area under the curve = 0.62-0.63, P = 0.01-0.06). With none of the measuring methods did the ROC curves point to any unique cut-off values, but indicated a wide range of possible cut-offs. However, none of the MTV measurements was prognostic for PFS (Hazard ratio 1.2-1.5, P = 0.15-0.52) or OS (Hazard ratio 1.0-1.5, P = 0.95 - 0.27). Conclusion: Baseline MTV as determined by different means, is a predictive factor for early response to eBEACOPP after two cycles. However, value as a prognostic factor after highly effective PET-2 adapted treatment strategy could not be observed.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mettler J, Müller H, Voltin CA, et al. Metabolic Tumour Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. J Nucl Med. 2018. PMID: 29880508. doi:10.2967/jnumed.118.210047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。